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ABSTRACT 
Background: Despite oral anticoagulation being highly effective in reducing stroke and 
thromboembolism, patients with atrial fibrillation (AF) still have a significant residual excess in 
mortality risk.  Additional management strategies are needed to reduce the mortality risk seen in AF 
patients. 
Methods: Ancillary analysis from the EURObservational Research Programme Atrial Fibrillation 
(EORP-AF) General Pilot Registry, to evaluate 1-year outcomes in AF patients according to statin 
use at baseline. 
Results: Of 2636 patients, 1286 (48.8%) patients used statins at baseline. Patients prescribed statins 
had more comorbidities. At 1-year follow-up, logistic regression analysis adjusted for AF type, 
symptomatic status and CHA2DS2-VASc score demonstrated that statin use was inversely 
associated with CV death (odds ratio [OR]: 0.50, 95% confidence interval [CI]: 0.30-0.82, 
p<0.0001), all-cause death (OR: 0.52, 95% CI: 0.37-0.73, p<0.0001) and the composite outcome of 
CV death/any thromboembolic event/bleeding (OR: 0.71, 95% CI: 0.52-0.98, p<0.0001).  Similar 
findings were observed for ‘high risk’ subgroups including the elderly, primary prevention and high 
thromboembolic risk AF patients.  
Survival analysis showed that statins prescribed patients had a lower risk of all-cause death at 
follow-up (p=0.0433). Multivariate Cox regression analysis found that statin use remained 
independently associated with a lower risk for all-cause death (hazard ratio [HR]: 0.61, 95% CI: 
0.42-0.88, p=0.0077). 
Conclusions: Statin use in AF patients was associated with improved outcomes, with an 
independent association with a lower risk of all-cause death at 1-year follow-up. 
 
Keywords: atrial fibrillation; statin therapy; cardiovascular events; all-cause death. 
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1. INTRODUCTION 
Atrial fibrillation (AF) is a well-established risk factor for higher morbidity and mortality, 
particularly from stroke and thromboembolic events (TE).[1] Oral anticoagulation is highly 
effective in reducing stroke and thromboembolism, but patients with AF still have a significant 
residual excess in mortality risk.[2–4]  This residual excess in mortality risk merits consideration of 
additional clinical management strategies.[5,6] 
 
Use of statins for both primary and secondary prevention of cardiovascular (CV) and 
cerebrovascular disease is well established[7,8] and is recommended in guidelines.[9,10] Statins 
reduce all-cause death, both in primary and secondary prevention, in the general population.[11,12]  
The pharmacological actions of statin go beyond the lipid-lowering effects,[13] with putative 
antithrombotic[14] and cardioprotective[15] actions.  Also, statin therapy seems to play an 
important role in preventing AF occurrences,[16] for example, in the post-operative[17] and post-
ablation[18] clinical scenarios. Such AF preventive actions are mediated through antioxidant and 
anti-inflammatory properties.[19] Statin treatment in AF patients reduces the risk of incident 
dementia[20], as well as the risk for all-cause death after an AF-related stroke.[21] Limited data are 
available about the use of statin in observational AF cohorts and their influence on major adverse 
outcomes. 
 
Thus, the aims to this ancillary analysis of the EURObservational Research Programme in Atrial 
Fibrillation (EORP-AF) General Registry Pilot Phase were to describe the use of statins in AF 
patients and the associated clinical profile, and second, to investigate the association of statin use 
with major adverse events and all-cause death over a 1-year follow-up observation period. 
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2. METHODS 
The EORP-AF General Registry is a prospective, observational, multicentre European-wide registry 
on AF patients in current cardiology practice conducted by the European Society of Cardiology 
(ESC).[22]  In brief, the EORP-AF Pilot Phase enrolled consecutive AF patients managed by 
cardiologists in nine ESC members’ European countries (Belgium, Denmark, Netherlands, Norway, 
Poland, Romania, Greece, Italy, and Portugal) from February 2012 to March 2013. Patients eligible 
for the study were both AF inpatients and/or outpatients referred to cardiology services (either 
hospital or office-based centres). Across the entire enrolment period, all patients consecutively 
presenting at every site were considered for eligibility. AF had to be recorded as a primary or 
secondary cardiovascular disease. Qualifying events were recorded by any electrocardiographic 
documentation occurring within the 12 months before the enrolment. Institutional review board for 
every institution approved study protocol. All patients entered the study after signing a written 
informed consent. Study was performed according to the EU Note for Guidance on Good Clinical 
Practice CPMP/ECH/135/95 and the Declaration of Helsinki. 
 
At the baseline, a full clinical and medication history was collected from any patient through 
clinical interview and/or access to clinical/hospital notes.  Over 13 months of enrolment, a total of 
3119 AF patients were collected. Follow-up procedures were performed according to the local 
procedures, via clinical interview, telephonic interview and hospital notes searching. During the 
pre-specified 1-year follow-up, ended in March 2014, the occurrence of major adverse events was 
recorded. All patients with available data on statin use at discharge/after consultation and follow-up 
observation were considered for this analysis. Thus, patients would have been already taking statins 
at the time of enrolment or prescribed statins during admission/consultation, according to 
physician’s clinical judgement. 
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Thromboembolic risk was defined according to the CHA2DS2-VASc score. ‘Low risk’ patients 
were defined as a CHA2DS2-VASc 0 in males or 1 in females; ‘moderate risk’ was defined as male 
patients with a CHA2DS2-VASc score 1; and ‘high risk’ was defined as CHA2DS2-VASc score ≥2. 
Bleeding risk was also assessed according to the HAS-BLED score. Symptomatic status at the 
baseline was defined according to European Heart Rhythm Association (EHRA) score. 
Accordingly, patients with EHRA I were considered as asymptomatic, while EHRA score from II to 
IV described patients progressively more symptomatic. Type of AF was defined as first detected, 
paroxysmal, persistent, long-standing persistent and permanent according to 2010 ESC guidelines 
on AF management.[23] 
 
2.1 Statistical Analysis 
Continuous variables were reported as mean±SD or as median and interquartile range (IQR). 
Among-group comparisons were made using a non-parametric test (Kruskal–Wallis test). 
Categorical variables were reported as percentages. Among-group comparisons were made using a 
chi-square test or Fisher’s exact test (if any expected cell count was less than five). For qualitative 
variables with more than two possibilities, the Monte Carlo estimates of the exact p-values are used. 
  
A stepwise forward multiple logistic regression was used to determine the clinical factors associated 
with statin use in AF patients at discharge/after consultation. From the baseline characteristics, we 
selected a list of covariates based on biological plausibility. Next, to obtain an accurate multivariate 
model, a univariate analysis was performed to select covariates to be include in the final 
multivariate model (all variables with p<0.10, see Supplemental Table 1). A significance level of 
0.05 is required to allow a variable into the model (SLENTRY=0.05) and a significance level of 
0.05 is required for a variable to stay in the model (SLSTAY=0.05). No interaction was tested. A 
Hosmer and Lemeshow Goodness-of-Fit test was used to verify that the model was optimal. A 
backward model was also performed to verify the results of the forward model. 
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A logistic regression analysis, adjusted for type of AF, symptomatic status (EHRA score) and 
thromboembolic risk (CHA2DS2-VASc score), was performed to establish the relationship with 
major adverse event occurrence according to statin use at baseline . Additional analyses were also 
performed according to the following specific subgroups: i) elderly patients (age≥75 years); ii) CV 
disease free patients (excluding those patients with previous coronary artery disease [CAD], 
previous coronary artery by-pass graft [CABG], previous myocardial infarction [MI], peripheral 
vascular disease, previous stroke/transient ischemic attack [TIA]); iii) patients with high 
thromboembolic risk (CHA2DS2-VASc score ≥2). The subgroups analyses were performed 
exploring interactions with the complementary subgroups (younger patients (age<75 years), 
patients with CV disease history and patients with CHA2DS2-VASc score <2). 
 
Plots of the Kaplan-Meier curves for time to all-cause death according to statin use were performed. 
The survival distributions have been compared using the Log-Rank test. A stepwise Cox model was 
used to determine the predictors of all-cause death during follow-up. From the baseline 
characteristics, we selected a list of covariates based on biological plausibility. Next, to obtain an 
accurate multivariate model, a univariate analysis was performed to select covariates to be included 
in the final model (all variables with p<0.10, see Supplemental Table 3). A significance level of 
0.05 is required to allow a variable into the model (SLENTRY=0.05) and a significance level of 
0.05 is required for a variable to stay in the model (SLSTAY=0.05). No interaction was tested. A 
Hosmer and Lemeshow Goodness-of-Fit test was used to verify that the model was optimal. A 
backward model was then performed to verify the results of the forward one. 
A two-sided p<0.05 was considered statistically significant. All analyses were performed using 
SAS statistical software version 9.3 (SAS Institute, Inc., Cary, NC, USA) in 2016.
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3. RESULTS 
Among the overall population of 3119 patients, 2636 (84.5%) were eligible for this analysis, while 
for the remaining 483 (15.5%) data about statin use were missing. Accordingly, 1286 (48.8%) were 
prescribed with a statin at discharge/after consultation. By-centre variability of prescription rate was 
wide, ranging from 0% to 84%, with a median [IQR] prescription of 50 [34-62] %. Prescription 
rates ranged from 33.3% in Norway to 62% in Romania [Supplemental Figure 1].  
 
Baseline characteristics according to statin prescription are reported in Table 1. Patients prescribed 
statins were older (p<0.0001) and more frequently overweight and obese (p<0.0001). A difference 
in distribution of types of AF, with patients prescribed with statins more likely to have paroxysmal 
and long-standing persistent AF, while non-statin users were more likely to have first detected, 
persistent and permanent AF (p=0.0155). Among classical CV risk factors, patients prescribed 
statins had more prevalent hypertension, hypercholesterolemia and diabetes mellitus (p<0.0001), as 
well as CAD, previous MI and previous percutaneous transluminal coronary angioplasty 
(PTCA)/CABG (all p<0.0001). Patients using statins at discharge were also more likely found to 
have chronic kidney disease than those not using statins (p=0.0080). Also, previous stroke/TIA 
(p=0.0002), peripheral vascular disease (p=0.0002) and chronic heart failure (CHF) (p<0.0001) 
were more prevalent in patients prescribed with statins compared to non-users.  Accordingly, 
patients prescribed with statins had both higher bleeding and thromboembolic risks (both 
p<0.0001), as well as higher proportions categorised as high bleeding or thromboembolic risk (both 
p<0.0001). 
 
At discharge/after consultation (Table 1), statin users were more frequently treated with at least one 
antithrombotic drug (p<0.0001), as well as more use of aspirin (p<0.0001) compared to non-users. 
At least one antiarrhythmic drug was more frequently used in patients prescribed statins 
(p=0.0032).  While class III antiarrhythmic drugs were more commonly used in patients prescribed 
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statins (p<0.0001), class I antiarrhythmic drugs were more used in non-users of statins (p=0.0020). 
Statin users were more commonly treated with angiotensin-converting-enzyme 
inhibitors/angiotensin receptor blockers, beta blockers, diuretics (all p<0.0001), dihydropyridine 
(DHP) calcium-channel blockers (p=0.0001), while non-DHP calcium-channel blockers were less 
likely used by statins users (p=0.0064). 
 
After a univariate analysis (Supplemental Table 1), a logistic regression model was compiled to 
describe the clinical factors associated with prescription of statin. The final multivariate forward 
model (Table 2) found prescription of statin at discharge/after consultation in AF patients was 
independently associated with the presence of hypercholesterolemia (p<0.0001), overweight 
(p=0.0034) and obese (p=0.0002) weight classes, as well as a clinical history of CAD (p<0.0001) 
and previous stroke/TIA (p=0.0279).  Being underweight (p=0.0231) was inversely associated with 
statin prescription. Repeating the analysis with a backward model found no difference in 
association between covariates considered and statin prescription (data not shown). 
 
3.1 Follow-up and Survival Analysis 
Data on AF progression were available for 659 (95.2%) out of 692 patients with paroxysmal AF at 
baseline. Patients with paroxysmal AF at baseline that became persistent, long-standing persistent 
or permanent AF were considered ‘progressors’ with regard to arrhythmia progression, while those 
remaining in paroxysmal AF were considered as ‘non-progressors’. There was no significant 
difference for statin use at baseline between progressors and non-progressors (52.6% vs. 49.8%, 
p=0.6162). 
 
During the pre-specified 1-year follow-up (Supplemental Table 2), patients prescribed with statin 
had a lower rate of all-cause death (p=0.0545), while no other significant differences were noted for 
the other outcomes. Logistic regression analysis (Table 3), adjusted for type of AF, EHRA score 
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and CHA2DS2-VASc score, found that statin prescription was inversely associated with CV death 
(p<0.0001), all-cause death (p<0.0001) and the composite outcome of CV death, any TE or 
bleeding (p<0.0001). Only a trend for significance was found for the occurrence of bleeding alone 
(p=0.0673), while no reduction in any TE occurrence was reported for statin treatment (p=0.0494).  
 
Kaplan-Meier curves [Supplemental Figure 2] showed, according to Log-Rank test, that patients 
prescribed with statins had a lower risk for all-cause death at 1-year follow-up (p=0.043). A 
multivariate Cox regression analysis was performed based on variables identified on univariate 
analysis (Supplemental Table 3). The final model (Table 4) found that statin prescription was 
associated with a lower risk of all-cause death (p=0.0077), independent of age (p<0.0001), 
permanent AF (p=0.0011), diabetes mellitus (p=0.0001), previous MI (p=0.0001), CHF (p<0.0001), 
symptomatic status (p=0.0231), occasional (p=0.0001) or regular (p=0.0001) physical activity and 
concomitant treatment with angiotensin-converting-enzyme inhibitors/angiotensin receptor blockers 
(p<0.0001). The inverse association between statin use and all-cause death was independent of both 
antithrombotic and antiplatelet drugs.  Repeating the analysis with a backward model found no 
difference in association between covariates considered and all-cause death (data not shown). 
 
3.2 Additional Subgroup Analyses 
The following ‘high risk’ specific subgroups were considered: i) elderly patients (age≥75 years); ii) 
CV disease free patients (excluding those patients with previous coronary artery disease [CAD], 
previous coronary artery by-pass graft [CABG], previous myocardial infarction [MI], peripheral 
vascular disease, previous stroke/TIA); iii) patients with high thromboembolic risk (CHA2DS2-
VASc score ≥2). 
 
In elderly patients, as well as for the high thromboembolic ones, those prescribed with statins had a 
lower rate for both CV death (p=0.0396 and p=0.0426, respectively) and all-cause death (p=0.0278 
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and p=0.0029, respectively) (Supplemental Table 4). In the CV disease free subgroup, a significant 
lower rate of events was found for all-cause death (p=0.0017) and the composite outcome of all-
cause death or any TE (p=0.0084); only a trend for significance was found for the CV death 
outcome (p=0.0618) (Supplemental Table 4). 
 
A logistic analysis (Supplemental Table 5), adjusted for type of AF, EHRA score and CHA2DS2-
VASc score, found that similar to the overall cohort, statin prescription was inversely associated 
with risk of CV death and all-cause death in elderly patients and also, the composite outcome of CV 
death, any TE or bleeding in CV disease free and high thromboembolic risk patients. Interaction 
analyses within the considered subgroups and the complementary subgroups did not show any 
significant differences, except for a trend for a lower risk for all-cause death in CV disease free 
patients of borderline statistical significance. 
 
4. DISCUSSION 
 
In this study, we found that 48.8% of European AF patients enrolled in the EORP-AF registry were 
prescribed with statins at discharge/after consultation. As expected, AF patients prescribed with 
statins had more major CV risk factors (hypercholesterolemia, obesity) and CV and cerebrovascular 
comorbidities. Importantly, statin prescription was inversely associated with the occurrence of CV 
death, all-cause death and a composite outcome of all-cause death, any TE or bleeding. These 
results were also found in the elderly (age≥75 years), CV disease free and high thromboembolic 
risk patients’ subgroups. Indeed, use of statins was independently associated with a lower risk of 
all-cause death at 1-year follow-up (39% of relative risk reduction [RRR]). 
 
The clinical profile of AF patients prescribed with statin resembles the recommendations of current 
guidelines, especially for secondary prevention whether for CAD,[9,24] stroke/TIA[25] or major 
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CV risk factors, as well as for hypercholesterolemia and obesity.[9,10] In AF management 
guidelines, use of statins as “upstream therapy” is mainly considered for AF primary prevention, 
even if stated that patients without any previous CV disease should not be treated.[26,27]  The ESC 
guidelines also suggest that we consider use of statins in AF secondary prevention, even if with a 
very low quality of evidence.[26] 
 
Our results suggest an association of statin use with a lower rate of major adverse events (i.e. CV 
death, all-cause death and the composite outcome of CV death, any TE or bleeding), even amongst 
elderly patients and in those without previous CV disease and at high thromboembolic risk. 
Opinions about statin use in elderly patients have been conflicting.[28–30] In particular, a large 
meta-analysis of elderly patients found that despite a reduction in major adverse events (MI relative 
risk [RR]: 0.606, 95% CI: 0.434-0.847; stroke RR: 0.762, 95%CI: 0.626-0.926), no beneficial effect 
was noted in terms of CV and all-cause death (RR: 0.907, 95% CI: 0.686-1.199 and RR: 0.941, 
95% CI: 0.856-1.035, respectively).[29] Moreover, caution was advised in balancing risks and 
benefits when deciding to treat or not to treat an elderly patient with a statin, especially with the 
potential for altered metabolism, drug-drug interactions, etc. amongst the elderly.[9,30] Our data 
seem to show that in elderly AF patients, treatment with statins seems to be beneficial in reducing 
major adverse outcomes, for both CV and all-cause death. Interestingly, we did not found any 
significant difference according to statin use on stroke or any TE occurrence. Notwithstanding that 
our study was not powered to detect differences in events occurrence, these data could suggest how 
despite a relevant CV risk can be identified in AF patients, stroke risk is mostly due to embolic risk 
rather than vascular disease, per se. 
 
As previously stated, the beneficial effect of statins in reducing major adverse events in the general 
population, both in primary and secondary prevention have been shown.[7,12] A comprehensive 
network meta-analysis including data from 199721 patients, reported strong evidence for statins in 
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reducing major adverse events (OR: 0.69, 95% CI: 0.64-0.75) and all-cause death (OR: 0.87, 95% 
CI: 0.82-0.92).[11] This effect was consistent both in primary (OR: 0.69, 95% CI: 0.61-0.79 and 
OR: 0.91, 95% CI: 0.83-0.99, respectively for major adverse events and all-cause death) and 
secondary prevention (OR: 0.69, 95% CI: 0.62-0.77 and OR: 0.82, 95% CI: 0.75-0.90, respectively 
for major adverse events and all-cause death).[11] 
 
Results from our study confirm that, even in AF patients, a possible benefit related to statin use in 
reducing major adverse events seems to be consistent across the various clinical scenarios. Indeed, 
both CV disease free patients and high thromboembolic ones had a RRR ranging from 30% to 70% 
according to the various outcomes. Also, the non-significant differences found in the interaction 
analysis seems to reinforce the suggestion that use of statin could be associated with a lower risk of 
major outcomes regardless of clinical characteristics. Moreover, Cox regression analysis confirmed 
the favourable association of statin use with improved clinical outcomes, independent of various 
clinical factors related to all-cause death in AF patients.  
 
Accumulating evidence has shown that statins have beneficial effects beyond their mere lipid-
lowering effects.[15] For example, statins may beneficially alter the thrombotic/ inflammatory/ 
oxidative state seen in cardiovascular disease.[13,14] Furthermore, statins may provide myocardial 
protection[15] and the anti-inflammatory effect could play a pivotal role in modulating an AF-
related inflammatory state.[31] Also, statins also modulate the detrimental effect of stroke 
occurrence in AF patients; for example, in a large cohort of AF patients presenting with an ischemic 
stroke, use of statins was inversely associated with risk of severe strokes, based on functional 
evaluation[32]. 
 
Our results could be interpreted as reinforcing the concept that AF would be considered as a 
vascular disease/risk factor itself. Recently, there have been an increasing body of evidence 
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suggesting a strong association between AF and cardiac or vascular disease.[33–35] One 
comprehensive systematic review and meta-analysis recently investigated the relationship between 
AF and several cardiovascular events and outcomes.[4] The latter found that AF was significantly 
associated with all major cardiovascular events, including peripheral arterial disease (RR: 1.31, 
95% CI: 1.19-1.45), ischemic heart disease (RR: 1.61, 95% CI: 1.38-1.87), cardiovascular mortality 
(RR: 2.03, 95% CI: 1.79-2.30) and heart failure (RR: 4.99, 95% CI: 3.04-8.22), as well as vascular-
related events such as chronic kidney disease (RR: 1.64, 95% CI: 1.41-1.91).[4] A recent meta-
analysis reported how >50% of deaths in AF were related to cardio-vascular reasons that were 
different than thromboembolic or bleeding events.[36] Thus, we could hypothesize that the 
supposed benefit of statin use in AF patients could be related to their ability in modulating vascular 
disease burden. Thus, the use of statins for treatment of AF patients could help reduce the excess 
mortality risk that remains despite anticoagulation.[5,6] Additional studies investigating the 
possible mechanistic pathways, are still needed to clarify the precise mechanisms by which statins 
show their benefits in the AF population.  Interestingly, our data are consistent with previous 
evidence from patients post-coronary artery by-pass graft surgery with AF whereby statins resulted 
in reductions of both short- and long-term mortality.[37] 
 
Our data showed a reduction in risk of major adverse events associated to the use of statin, perhaps 
even stronger than most of the interventional trials testing statins. Also, considering that patients 
using statins reported a higher prevalence of most comorbidities, we could hypothesize that the 
strong reduction in risk could be partially explained by a stronger treatment intensity and/or more 
intensive risk factorsmanagement, eventhough the multivariate analysis did consider the most 
relevant risk factors and the main cardioprotective pharmacological treatments. 
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4.1 Limitations 
The observational nature of our study is the main limitation to generalizability of our results. 
Moreover, EORP-AF has not been powered to detect differences in the specified subgroups and the 
relatively small number of patients, as well as the non-randomised nature of statin allocation are 
major limitations to our study.  Furthermore, the relatively short follow-up and the missing data on 
statin use for around 15% of patients originally enrolled, have to be considered as limitations of this 
analysis. Enrolling procedures in EORP-AF were based on management by cardiologists, so it 
could not fully represent the entire AF population. Furthermore, we have no specific data about use 
of the different statins and doses or adherence to prescriptions, which would have allowed a deeper 
and more detailed analysis of their effects. Also, we do not have any data to see if there was any 
difference in terms of other medical management (e.g. number/frequency of clinical reviews) 
during the 1-year follow-up. Residual confounders for factors which we cannot fully account for, 
are additional limitations. Finally, given the lack of specific laboratory data, our study cannot 
establish any direct causal pathophysiological link between use of statins and outcomes in AF, but 
associations that would-be hypothesis generating.   
 
5. CONCLUSIONS  
Use of statins among AF patients was found to be associated with improved outcomes, with an 
independent association with a lower risk for all-cause death occurrence at 1-year follow-up.  
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Table 1: Baseline characteristics according to statin use at discharge/after consultation 
 Statins 
n= 1286 
No Statins 
n= 1350 
p 
Age years, median [IQR] 70.0 [64.0-77.0] 69.0 [60.0-77.0] <0.0001 
Female, n (%) 488 / 1286 (37.9) 556 / 1350 (41.2) 0.0893 
BMI, n (%)    
Underweight 4 / 1258 (0.3) 24 / 1304 (1.8) <0.0001 
Normal weight 302 / 1258 (24.0) 417 / 1304 (32.0)  
Overweight 544 / 1258 (43.2) 537 / 1304 (41.2)  
Obese 408 / 1258 (32.4) 326 / 1304 (25.0)  
Type of AF, n (%)    
First detected 362 / 1262 (28.7) 410 / 1322 (31.0) 0.0155 
Paroxysmal 352 / 1262 (27.9) 340 / 1322 (25.7)  
LS Persistent 75 / 1262 (5.9) 45 / 1322 (3.4)  
Persistent 260 / 1262 (20.6) 289 / 1322 (21.9)  
Permanent 213 / 1262 (16.9) 238 / 1322 (18.0)  
Hypertension, n (%) 1007 / 1276 (78.9) 845 / 1345 (62.8) <0.0001 
Hypercholesterolemia, n (%) 976 / 1261 (77.4) 260 / 1313 (19.8) <0.0001 
Diabetes mellitus, n (%) 336 / 1278 (26.3) 200 / 1343 (14.9) <0.0001 
Current smoker, n (%) 140 / 1247 (11.2) 147 / 1307 (11.2) 0.9871 
Alcohol ≥2-3 units/day, n (%) 91 / 1198 (7.6) 116 / 1258 (9.2) 0.1474 
Coronary artery disease, n (%) 622 / 1154 (53.9) 201 / 1134 (17.7) <0.0001 
Previous Myocardial infarction, n (%) 278 / 1154 (24.1) 85 / 1134 (7.5) <0.0001 
Previous PTCA/CABG, n (%) 306 / 1154 (26.5) 82 / 1134 (7.2) <0.0001 
Previous stroke/TIA, n (%) 148 / 1268 (11.7) 100 / 1345 (7.4) 0.0002 
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Peripheral vascular disease, n (%) 174 / 1231 (14.1) 118 / 1265 (9.3) 0.0002 
Chronic heart failure, n (%) 654 / 1267 (51.6) 501 / 1246 (40.2) <0.0001 
Chronic Kidney Disease, n (%) 191 / 1283 (14.9) 153 / 1343 (11.4) 0.0080 
Symptomatic status, n (%) 1286 1350  
EHRA I 539 / 1286 (41.9) 544 / 1350 (40.3) 0.3991 
EHRA II-IV 747 / 1286 (58.1) 806 / 1350 (59.7)  
Physical activity, n (%)    
None 443 / 1184 (37.4) 506 / 1253 (40.4) 0.0017 
Occasional 453 / 1184 (38.3) 393 / 1253 (31.4)  
Regular 243 / 1184 (20.5) 284 / 1253 (22.7)  
Intense 45 / 1184 (3.8) 70 / 1253 (5.6)  
HAS-BLED, median [IQR] 1.0 [1.0-2.0] 1.0 [0.0-2.0] <0.0001 
0-2 1077 / 1286 (83.7) 1197 / 1350 (88.7)  
>=3 209 / 1286 (16.3) 153 / 1350 (11.3)  
CHA2DS2-VASc, median [IQR] 4.0 [2.0-5.0] 3.0 [1.0-4.0] <0.0001 
Low TE Risk 32 / 1286 (2.5) 187 / 1350 (13.9)  
Medium TE Risk 103 / 1286 (8.0) 175 / 1350 (13.0)  
High TE Risk 1151 / 1286 (89.5) 988 / 1350 (73.2)  
Therapy at discharge/after consultation    
Antithrombotic therapy, n (%)    
At least one 1262 / 1285 (98.2) 1263 / 1348 (93.7) <0.0001 
Antiplatelet 601 / 1284 (46.8) 278 / 1349 (20.6) <0.0001 
Any OAC 1054 / 1283 (82.2) 1087 / 1348 (80.6) 0.3190 
VKA 959 / 1283 (74.7) 979 / 1349 (72.6) 0.2057 
NOACs 95 / 1285 (7.4) 109 / 1349 (8.1) 0.5096 
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Antiarrhythmic drugs, n (%)    
At least one 488 / 1286 (37.9) 438 / 1349 (32.5) 0.0032 
Antiarrhythmic class I 105 / 1286 (8.2) 159 / 1350 (11.8) 0.0020 
Antiarrhythmic class III 388 / 1286 (30.2) 278 / 1349 (20.6) <0.0001 
ACEi/ARBs, n (%) 956 / 1286 (74.3) 738 / 1347 (54.8) <0.0001 
Beta Blockers, n (%) 959 / 1285 (74.6) 878 / 1347 (65.2) <0.0001 
Diuretics, n (%) 727 / 1286 (56.5) 621 / 1348 (46.1) <0.0001 
DHP calcium-channel blockers, n (%) 204 / 1285 (15.9) 146 / 1349 (10.8) 0.0001 
Non-DHP calcium-channel blockers, n (%) 64 / 1285 (5.0) 102 / 1349 (7.6) 0.0064 
Digoxin, n (%) 237 / 1286 (18.4) 282 / 1349 (20.9) 0.1103 
Legend: AF= atrial fibrillation; ARB= angiotensin receptor blocker; BMI= body mass index; 
CABG= coronary artery by-pass graft; DHP= dihydropyridine; EHRA= European Heart Rhythm 
Association; IQR= interquartile range; LS= long standing; NOACs= non-vitamin K antagonist oral 
anticoagulants; OAC= oral anticoagulant; PTCA= percutaneous transluminal coronary angioplasty; 
TIA= transient ischemic attack; VKA= vitamin K antagonist.  
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Table 2: Multivariate logistic regression analysis for clinical factors associated with statin use at 
discharge/after consultation 
 Odds Ratio 95% CI P 
BMI    
Underweight 0.19 0.05-0.80 0.0231 
Normal weight (reference) - - - 
Obese 1.75 1.31-2.35 0.0002 
Overweight 1.50 1.14-1.96 0.0034 
Hypercholesterolemia 12.77 10.26-15.89 <0.0001 
Coronary artery disease 4.22 3.32-5.36 <0.0001 
Previous stroke/TIA 1.52 1.05-2.22 0.0279 
Legend: BMI= body mass index; CI= confidence interval; TIA= transient ischemic attack. 
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Table 3: Logistic regression analysis for statin effect on adverse outcomes at 1-year follow-up
a
 
 Odds Ratio 95% CI P 
Stroke/TIA 0.74 0.31-1.80 0.2021 
Any TE
b
 1.10 0.71-1.72 0.0494 
Bleeding 0.51 0.22-1.18 0.0673 
CV death 0.50 0.30-0.82 <0.0001 
All-cause death 0.52 0.37-0.73 <0.0001 
CV death - any TE or Bleeding 0.71 0.52-0.98 <0.0001 
Legend: 
a
adjusted for type of AF, EHRA score and CHAD2DS2-VASc score; 
b
Stroke, TIA, ACS, 
coronary intervention, cardiac arrest, peripheral embolism and pulmonary embolism; AF= atrial 
fibrillation; CI= confidence interval; CV= cardiovascular; TE= thromboembolism; TIA= transient 
ischemic attack.  
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Table 4: Cox multivariate regression analysis for all-cause death at 1-year follow-up 
 Hazard Ratio 95% CI P 
Statins 0.61 0.42-0.88 0.0077 
Age (per year) 1.05 1.03-1.08 <0.0001 
Type of AF    
First Reported (reference) - - - 
Paroxysmal 0.63 0.37-1.06 0.0823 
Persistent 0.83 0.50-1.36 0.4504 
LS Persistent 0.69 0.27-1.77 0.4419 
Permanent 0.46 0.29-0.73 0.0011 
Diabetes mellitus 2.02 1.41-2.89 0.0001 
Myocardial infarction 2.11 1.44-3.10 0.0001 
Chronic heart failure 2.97 1.99-4.45 <0.0001 
EHRA II-IV (vs EHRA I) 0.65 0.45-0.94 0.0231 
Physical activity    
None - - - 
Occasional 0.43 0.28-0.66 0.0001 
Regular 0.19 0.07-0.46 0.0003 
Intense 0.69 0.21-2.22 0.5309 
ACEi/ARBs 0.49 0.34-0.69 <0.0001 
Legend: ACEi= angiotensin converting enzyme inhibitor; AF= atrial fibrillation; ARB= 
angiotensin receptor blocker; CI= confidence interval; EHRA= European Heart Rhythm 
Association. 
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